• Subscribe
  • About us
  • Advertise with us

NeuroSens

Menu

Skip to content
  • Home
  • Neurology
  • Psychiatry

Topic: MS

Disease-modifying therapies in MS: long-term data

May 10, 2017  

AAN 2017 DAILY REPORT

April 27, 2017  

MS Sequencing: Part 4 – What is the treatment plan?

April 19, 2017  

FDA approves ocrelizumab in RRMS, PPMS

March 30, 2017  

Neurologists cautious about patient e-contact: survey

March 15, 2017  

Daclizumab approved in Canada for relapsing MS

March 3, 2017  

MS Sequencing: Part 3 – Evaluating treatment response

February 16, 2017  

NEUROSOUND: CHARCOT 2016 HIGHLIGHTS

January 25, 2017  

MS Sequencing: Part 2 – Treatment initiation

January 12, 2017  

Sun avoidance – more harm than good?

December 16, 2016  
Previous
24
25
26
27
28
Next

Browse by Topic

  • MS (414)
  • CLINICAL CASES IN MS (16)
  • EPILEPSY (36)
  • BIOMARKERS IN MS (54)
  • AAN 2025 (5)
  • ACTRIMS 2025 (6)
  • Library (17)
  • AES 2024 (1)
  • ECTRIMS 2024 (6)
  • EAN 2024 (3)
  • AD (85)
  • AAN 2024 (5)
  • ACTRIMS Forum 2024 (2)
  • PD (77)
  • COVID-19 (58)
  • MIGRAINE (25)
  • DEPRESSION (36)
  • STROKE (22)
  • SCHIZOPHRENIA (25)
  • DEMENTIA (10)
  • SLEEP (2)
  • PAIN (3)
  • BPD (4)
  • ALS (1)

Popular Posts

  • DMT prescribing in Canada – survey results posted on June 6, 2025
  • CLINICAL CASES IN MS: A 42 Y.O. WOMAN WITH A SEVERE RELAPSE ON DMF posted on June 2, 2025
  • Proton pump inhibitors linked to neurological conditions posted on November 29, 2019
Copyright 2025 Lind Publishing Inc All rights reserved. Developed by Integration New Media, INC. (INM)
Contact Us Terms and Conditions